Injecting Mounjaro every 2 weeks: what the licensed schedule actually says

What the trial data say about dosing frequency

The clinical case for tirzepatide rests almost entirely on weekly dosing. SURMOUNT-1, published in the New England Journal of Medicine, ran for 72 weeks and recorded average body-weight reductions of around 20–21% at the 15mg dose, figures that are now cited in NICE's appraisal of tirzepatide (TA1026) and in the medicine's UK Summary of Product Characteristics. Every participant in that programme injected once a week. There is no published randomised evidence for fortnightly tirzepatide in weight management. That is not a technicality; it is a meaningful gap. Without comparable trial data, neither a prescriber nor a regulator can say what results, risks or dose requirements apply to a two-week interval.

Tirzepatide's pharmacokinetics explain part of why. The molecule has a plasma half-life of approximately five days, which means that by day 14, drug levels have declined substantially. The stable therapeutic range assumed by the licensed dosing schedule simply does not hold across a fortnight. That matters both for efficacy and for tolerability: erratic levels can change how side effects are experienced.

If you have ever missed a weekly injection and wondered about timing, the guidance on weekly injection timing covers what the official advice says about minor scheduling shifts.

What the prescriber's SmPC actually permits for a missed dose

The Mounjaro SmPC does contain missed-dose guidance, and it is worth knowing because it is often misread. If a dose is missed, you may take it within four days of the scheduled day. Beyond that four-day window, skip it and resume on the original weekly schedule. That means in the worst case, a missed dose extends your cycle to about eleven days, not fourteen. The instruction to skip and return to schedule rather than inject late is precisely designed to avoid a creeping drift toward fortnightly dosing.

The Mounjaro injection overview covers practical administration in more detail, including site rotation and storage. For questions about other interval adjustments people sometimes attempt, the pages on injecting every four days or every five days address those specific queries with the same pharmacological context.

Why people consider stretching doses, and a better alternative

It is understandable. Needles can feel daunting. Some weeks life is genuinely chaotic. Or a pen has run out earlier than expected and the next supply has not yet arrived. These are real situations, and they are not unusual. Feeling uncertain about the weekly commitment is not a reason to feel embarrassed; it is a reason to talk.

Adjusting your own dosing schedule without clinical guidance is a different matter. It is not covered by your prescription, it is not covered by the evidence, and if something goes wrong, your prescriber cannot meaningfully support you because they did not agree to that plan. The NHS tirzepatide page is clear that the once-weekly schedule should be followed as directed.

If supply continuity is part of the concern, it is worth understanding how the private market is priced and what is included in different services, the Mounjaro price comparison guide explains what to look for beyond the headline number. If needle anxiety is the issue, that too is a clinical conversation: a prescriber can discuss injection technique, pen choice, and whether any additional support would help.

The team at nume includes GPhC-registered Independent Prescribers who review every consultation personally. If your circumstances have changed or you have concerns about your current schedule, speaking to our prescribers is the right first step. You can also read more about the broader Mounjaro treatment overview or explore how it fits into weight management approaches more generally.